Searchable abstracts of presentations at key conferences in endocrinology

ea0093oc2 | Oral communication 1: Adrenal Diseases | EYES2023

Morbidity in patients with chronic adrenal insufficiency – cardiovascular risk factors and hospitalization rate compared to population based controls

Chifu Irina , Quinkler Marcus , Altieri Barbara , Hannemann Anke , Volzke Henry , Lang Katharina , Reisch Nicole , Pamporaki Christina , Willenberg Holger S. , Beuschlein Felix , Burger-Stritt Stephanie , Hahner Stefanie

Objective: Patients with adrenal insufficiency (AI) have been found to have increased cardiovascular morbidity, partly associated with nonphysiologic glucocorticoid replacement.Design: We included two separate cohorts (cohort 1 and 2) of patients with chronic primary and secondary AI under standard replacement therapy and compared them to two age- and sex-matched population-based studies (SHIP-TREND/DEGS). Patient cohort 1 comprised 389 individuals asses...

ea0099p27 | Adrenal and Cardiovascular Endocrinology | ECE2024

Impact on immunophenotype of switching from conventional glucocorticoids to modified-release hydrocortisone in congenital adrenal hyperplasia

Ziegler Selina , Nowotny Hanna , Choi Hannah , Tschaidse Lea , Auer Matthias , Welp Ann-Christin , Gottschlich Adrian , Kobold Sebastian , Rothenfusser Simon , Reisch Nicole

Background: Previous research has revealed variances in the composition of immune cells among patients with congenital adrenal hyperplasia (CAH) on conventional glucocorticoid (GC) replacement therapy compared to healthy controls. Modified-release hydrocortisone (MR-HC) optimizes cortisol pharmacokinetics, aligning with a more physiological circadian cortisol rhythm. This study therefore aims to assess the impact on the immune cell profile when transitioning patients with CAH ...

ea0099p237 | Adrenal and Cardiovascular Endocrinology | ECE2024

Fertility outcomes in women with classic and non-classic congenital adrenal hyperplasia on modified-release hydrocortisone (MR-HC)

Tschaidse Lea , Nowotny Hanna F , Auer Matthias , Lottspeich Christian , Welp Ann-Christin , Bidlingmaier Martin , Hawley James M , Keevil Brian , Reisch Nicole

Background: Women with classic and non-classic (NC) congenital adrenal hyperplasia (CAH) often struggle with fertility, due to androgen excess, elevated progesterone and 17-hydroxyprogesterone (17OHP) levels, causing anovulation, impaired endometrial development and menstrual irregularities. The typical approach to addressing infertility so far, often involves an increase in glucocorticoid (GC) doses, yet this strategy carries potential side effects. Limited observational data...

ea0081p259 | Adrenal and Cardiovascular Endocrinology | ECE2022

Outcome of COVID-19 infections in patients with adrenal insufficiency

Nowotny Hanna , Bryce Jillian , Giordano Roberta , Baronio Federico , Chifu Irina , Cools Martine , van den Akker Erica L.T. , Falhammar Henrik , Appelman-Dijkstra Natasha , Persani Luca , Beccuti Guglielmo , Glasberg Simona , Pereira Alberto M , Sverre Husebye Eystein , Hahner Stefanie , Ahmed Faisal , Reisch Nicole

Background: Only few cases of patients with adrenal disorders affected by coronavirus disease 2019 (COVID-19) have been reported so far. In this study, clinical outcome data of patients with adrenal disorders and COVID-19 infection has been collected by the ESE Rare Disease Committee and ENDO-ERN via the European Registries for Rare Endocrine Conditions (EuRRECa) project.Methods: This questionnaire included 32 questions on collecting quantitative and qua...

ea0086oc4.5 | Adrenal and Cardiovascular | SFEBES2022

Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control

Rees Aled , Merke Deborah , Arlt Wiebke , Pierriere Aude , Hirschberg Angelica , Juul Anders , Newell-Price John , Perry Colin , Prete Alessandro , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe , Coope Helen , Lewis Alexander , Porter John , Ross Richard

Introduction: First-line treatment for congenital adrenal hyperplasia (CAH) is hydrocortisone1. When adequate control is not achieved, prednisolone (or its prodrug prednisone) are often used. However, there has been no formal comparison of disease control in CAH comparing prednis(ol)one vs hydrocortisone and patients are often on a glucocorticoid dose that exceeds the guideline recommended dose of hydrocortisone (≤25 mg/day)1,2. We report an interim...

ea0090oc5.1 | Oral Communications 5: Adrenal and Cardiovascular Endocrinology 1 | ECE2023

CYP21A2-R484Q mice, a humanized mutant animal model for congenital adrenal hyperplasia

Ramkumar Thirumalasetty Shamini , Schubert Tina , Naumann Ronald , Reichardt Ilka , Rohm Marie Luise , Landgraf Dana , Gembardt Florian , Peitzsch Mirko , Hartmann Michaela F , Sarov Mihail , Wudy Stefan A , Reisch Nicole , Huebner Angela , Koehler Katrin

Congenital Adrenal hyperplasia (CAH) refers to a group of autosomal-recessive inherited disorders of impaired adrenal steroidogenesis. The most common form is 21-hydroxylase deficiency (21-OHD) caused by mutations in the CYP21A2 gene. Patients lack glucocorticoids and in some cases mineralocorticoids, and present with androgen excess causing hypoglycemia, live-threatening salt wasting, virilisation, and precocious puberty. Treatment includes the replacement of deficie...

ea0090p16 | Adrenal and Cardiovascular Endocrinology | ECE2023

Immunophenotypic differences in patients with primary adrenal insufficiency of different etiology

Nowotny Hanna F. , Marchant Seiter Thomas , Ju Jing , Gottschlich Adrian , Schneider Holger , Zopp Stephanie , Vogel Frederick , Tschaidse Lea , Auer Matthias , Lottspeich Christian , Kobold Sebastian , Rothenfuszer Simon , Beuschlein Felix , Reincke Martin , Braun Leah , Reisch Nicole

Background: Primary adrenal insufficiency (PAI) has been associated with increased risk of infection, adrenal crises and a higher mortality rate. This is caused by altered circadian cortisol profiles, which ultimately lead to immune cell dysregulation. In this study, we aim to characterize differences in immunophenotype of PAI patients of three different etiologies.Methods: Cross-sectional single center study including 28 patients with congenital adrenal...

ea0035s14.1 | Clinical outcome of medical intervention in Disorder of Sex Development (DSD) | ECE2014

dsd-LIFE: clinical European outcome study of disorders of sex development

Kohler Birgit , Arlt Wiebke , Bouvattier Claire , Chatelain Pierre , Grinten Hedi Claahsen van der , Cohen-Kettenis Peggy , Nordenstrom Anna , Pienkowski Catherine , Richter-Unruh Annette , Slowikowska-Hilczer Jolanta , Szarras-Capnik Maria , Reisch Nicole , Sultan Charles , Thyen Ute , Wiesemann Claudia

Disorders of sex development (DSD) include a conglomerate of rare conditions with discrepancy of the chromosomal, gonadal or phenotypic sex. Since the last 2 decades the genetic causes and the pathogenesis have been identified in many patients with DSD. Multidisciplinary clinical care as decision on the sex of rearing, genital surgery, hormone therapies and psychological support has a life-long impact on the affected persons. However, previous clinical outcome studies of DSD w...

ea0070oc1.2 | Adrenal and Cardiovascular Endocrinology | ECE2020

A Phase III randomized, controlled trial of a modified-release hydrocortisone formulation in the treatment of classic congenital adrenal hyperplasia

Merke Deborah , Mallappa Ashwini , Arlt Wiebke , de la Perriere Aude Brac , Hirschberg Linden Angelica , Juul Anders , Newell-Price John , Perry Colin , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Nike , Touraine Phillippe , Matlby Kerry , Treasure Peter , Porter John , Ross Richard

Background: Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD-CAH) have poor health outcomes due to failure of currently available glucocorticoid preparations to control adrenocorticotropic hormone-driven androgen excess. We investigated whether modified-release hydrocortisone (MR-HC), which mimics the physiological circadian cortisol rhythm, could improve androgen control.Methods: 122 patients with 21-OHD-CAH ...

ea0016p333 | Endocrine tumours | ECE2008

Deficits in the clinical management of patients with adrenocortical carcinoma in Germany

Johanssen Sarah , Koschker Ann-Cathrin , Hahner Stefanie , Quinkler Marcus , Saeger Wolfgang , Morcos Michael , Willenberg Holger , Langer Peter , Klose Silke , Reisch Nicole , Beuschlein Felix , Brauckhoff Michael , Fottner Christian , Wortmann Sebastian , Oelkers Wolfgang , Maeder Uwe , Fassnacht Martin , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Accordingly, in many cases, the attending doctors have no previous experience with the disease. The aim of our study was to evaluate the quality of care in a large number of patients with ACC in Germany. Data from 263 adult patients of the German ACC registry were analyzed with regard to the following parameters: time to diagnosis, hormonal assessment, imaging, histopathological documentation, follow-up. The...